CEO, Mark Hegarty, and CTO, Matthew Baker, were recently interviewed by 360Dx about Dxcover's ground breaking blood test for Brain Cancer.
They describe how the Brain Cancer Test has adjusted sensitivity and specificity, which can have clinical utility in different markets. In the US, Mark Hegarty sees more opportunities for a high-specificity screening test for early detection of brain cancer. With Ron Andrews now on board as a non-executive chair, Dxcover have recently bolstered their US presence and will continue to build their credibility in the US market.
To hear more, you can access the full article here: https://www.360dx.com/cancer/dxcover-aims-2025-debut-brain-cancer-tests-adjustable-sensitivity-and-specificity